Cartesian Therapeutics/$RNAC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
- Ticker
- $RNAC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 75
- Headquarters
- Frederick, United States
RNAC Metrics
BasicAdvanced
$194M
-
-$4.53
0.76
-
Price and volume
Market cap
$194M
Beta
0.76
52-week high
$11.00
52-week low
$5.60
Average daily volume
143K
Financial strength
Current ratio
8.377
Quick ratio
7.837
Long term debt to equity
-0.43
Total debt to equity
-0.462
Interest coverage (TTM)
-36.09%
Profitability
EBITDA (TTM)
-99.809
Gross margin (TTM)
-6,749.37%
Net profit margin (TTM)
-12,435.22%
Operating margin (TTM)
-10,009.17%
Effective tax rate (TTM)
6.73%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-19.23%
Return on equity (TTM)
153.28%
Valuation
Price to revenue (TTM)
174.674
Price to book
-1.49
Price to tangible book (TTM)
-0.71
Price to free cash flow (TTM)
-1.992
Free cash flow yield (TTM)
-50.21%
Free cash flow per share (TTM)
-3.191
Growth
Revenue change (TTM)
-6.05%
Earnings per share change (TTM)
143.70%
3-year revenue growth (CAGR)
-79.97%
What the Analysts think about RNAC
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
Analyst projections of the future price of Cartesian Therapeutics stock.
RNAC Financial Performance
Revenues and expenses
RNAC Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RNAC
Fund name | Fund size | $RNAC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.